Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 07/30
0.48 AUD   +1.05%
07/29IMMUTEP : Completion of Placement - Tranche 2
PU
07/26IMMUTEP : Results of EGM
PU
07/25IMMUTEP : 2021 EGM Presentation
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Immutep in Collaboration, Supply Agreement With Merck KGaA

06/01/2021 | 06:35am EDT

By Chris Wack

Immutep Limited is in a new collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, for a Phase I/IIa clinical trial in patients with solid tumors.

The biotechnology company said the trial will evaluate the feasibility, safety and efficacy of Immutep's lead product candidate, eftilagimod alpha, or IMP321, when given in combination with bintrafusp alfa, an investigational bifunctional fusion protein immunotherapy being jointly developed by Merck KGaA and GlaxoSmithKline.

Bintrafusp alfa aims to block two immunosuppressive pathways, TGF-<BETA> and PD-L1, while efti activates antigen presenting cells, via the LAG-3--MHC II pathway.

Immutep said the trial will be conducted by the Institute of Clinical Cancer Research, at Krankenhaus Nordwest in Frankfurt, Germany, as an investigator-initiated trial.

The study will be run as an amendment to the protocol of the ongoing Phase I trial as the fifth arm.

The trial is planned to take place in 2 clinical sites in Germany. Immutep is financially supporting the trial to be run by IKF, and Merck KGaA is financially contributing to the biomarker-related work. The first patient is expected to be enrolled in mid-2021 and the trial is expected to deliver first data in early 2022.

Immutep shares were up 10% to $5.56 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-01-21 0835ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -0.42% 34935.47 Delayed Quote.14.63%
GLAXOSMITHKLINE PLC 0.81% 1417.8 Delayed Quote.5.65%
IMMUTEP LIMITED 1.05% 0.48 End-of-day quote.15.66%
MERCK KGAA 0.23% 172.65 Delayed Quote.23.01%
All news about IMMUTEP LIMITED
07/29IMMUTEP : Completion of Placement - Tranche 2
PU
07/26IMMUTEP : Results of EGM
PU
07/25IMMUTEP : 2021 EGM Presentation
PU
07/21IMMUTEP : Raises over $5 Million in Share Purchase Plan
MT
07/20IMMUTEP : Completion of Share Purchase Plan
PU
07/16IMMUTEP : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the ..
PU
07/15IMMUTEP : Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - poster pr..
PU
07/14IMMUTEP : Quarterly Activities Report & Appendix 4C (Form 6-K)
PU
07/13IMMUTEP : Bell Potter - Creating Value with Phase 3 around the corner – In..
PU
07/13IMMUTEP : Quarterly Activities Report
AQ
More news
Financials
Sales 2021 5,24 M 3,85 M 3,85 M
Net income 2021 -28,4 M -20,8 M -20,8 M
Net Debt 2021 9,80 M 7,20 M 7,20 M
P/E ratio 2021 -11,4x
Yield 2021 -
Capitalization 408 M 300 M 300 M
EV / Sales 2021 79,8x
EV / Sales 2022 37,5x
Nbr of Employees -
Free-Float 98,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,48 AUD
Average target price 1,18 AUD
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
Frédéric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED15.66%300
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907